AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20965712
Drug: Budesonide/formoterol (400/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (400/12 μg)
Trial: 20965712
Drug: Formoterol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (12 μg)
Trial: 28469157
Drug: Deferiprone 10
RxNorm normalized name: deferiprone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone 10 mg/kg BID
Trial: 28469157
Drug: Deferiprone 15
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 15 mg/kg BID
Trial: 28469157
Drug: Deferiprone 30
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 30 mg/kg
Trial: 12037450
Drug: Calcipotriol ointment/scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment/scalp solution (80-100 g/week and 30-50 ml/week, respectively)
Trial: 139852
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg three times daily for 10-20 days)
Trial: 17584567
Drug: Thiazolidinedione therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazolidinedione therapy (pioglitazone or rosiglitazone)
Trial: 15089940
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide suspension [Ca(OH)2]
Trial: 11294429
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs post-operatively for 3-6 weeks
Trial: 9257419
Drug: Spreadsheet method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spreadsheet method for displaying drug dosing histories
Trial: 8177603
Drug: Sclero cryo
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclero cryo therapy
Trial: 29320587
Drug: Basic skin
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic skin care regimen following hyaluronic acid filler and neurotoxin treatment
Trial: 29320587
Drug: Nu‐Derm® skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nu‐Derm® skin care system (Obagi Medical Products, Inc) following treatment
Trial: 27097354
Drug: Low-dose albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose albumin plus terlipressin
Trial: 21309374
Drug: Sensory Integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Integration (SI) treatment group
Trial: 21309374
Drug: Fine motor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fine motor treatment group
Trial: 15080821
Drug: Desloratadine (DES)
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine (DES) 5 mg
Trial: 15151516
Drug: Fexofenadine (FEX)
RxNorm normalized name: fexofenadine Oral Tablet [Wal-Fex]
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine (FEX) 180 mg
Trial: 15080821
Drug: Levocetirizine (LEV)
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine (LEV) 5 mg
Trial: 11280457
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg azithromycin once a day for four days per month along with 0.05% topical tretinoin for a total of 12 weeks
Trial: 11280457
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxycycline daily in addition to topical 0.05% tretinoin cream for a total of 12 weeks
Trial: 8504628
Drug: Intravenous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous low dose aspirin (50 mg)
Trial: 8504628
Drug: Intravenous high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high dose aspirin (500 mg)
Trial: 3323256
Drug: A-49816 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-49816 (0.5 to 20 mg)
Trial: 31703936
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose (n=14)
Trial: 31703936
Drug: 1/5th dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/5th dose (n=17)
Trial: 31703936
Drug: 1/25th dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/25th dose (n=13)
Trial: 21961441
Drug: Constraint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint therapy plus electrical stimulation
Trial: 30284506
Drug: Constraint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint therapy
Trial: 12640257
Drug: Irbesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (angiotensin II type 1 receptor antagonist)
Trial: 12640257
Drug: Atenolol (beta1-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta1-adrenoceptor antagonist)
Trial: 10460983
Drug: Luffa comp.-Heel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luffa comp.-Heel nasal spray (0.14 ml per application, 4 times per day)
Trial: 10460983
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium spray (control)
Trial: 10460983
Drug: Luffa comp.-Heel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luffa comp.-Heel nasal spray
Trial: 10460983
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium spray
Trial: 2491883
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of ifosfamide
Trial: 2491883
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion schedule of ifosfamide
Trial: 2491883
Drug: Performance score
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance score 0-2 prior to chemotherapy
Trial: 2491883
Drug: Performance score
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance score 0-1 prior to chemotherapy
Trial: 31399883
Drug: Dry syrup
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry syrup formulation (2%, 1g containing 20mg of memantine hydrochloride)
Trial: 31399883
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet (reference product)
Trial: 17640415
Drug: Carob fibre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carob fibre (50 g)
Trial: 10095691
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of medication
Trial: 10095691
Drug: Patient-friendly drug
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-friendly drug leaflets
Trial: 7924772
Drug: Insulin-treated pregnant
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated pregnant women
Trial: 3094403
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HFJV with Intermittent Positive Pressure Ventilation (CV)
Trial: 26663590
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (200 mcg every 12 h)
Trial: 26663590
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (starting from 6 mU/min to maximum 40 mU/min)
Trial: 22979982
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 mg twice daily) for 4 weeks
Trial: 22979982
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) (500 mg once daily) for 4 weeks
Trial: 20223132
Drug: Intracapsular anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracapsular anesthesia (8 mL of 2% lidocaine) - Group B
Trial: 20223132
Drug: Oral clorazepate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clorazepate dipotassium (5 mg one hour before biopsy) - Group C
Trial: 18672400
Drug: PBT2 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBT2 50 mg
Trial: 25223369
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily
Trial: 18389900
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily (in patients not receiving stavudine)
Trial: 11524351
Drug: 9 mL
RxNorm normalized name: ethanol 6.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mL of 2% lidocaine
Trial: 9266230
Drug: Doxazosin (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1-4 mg o.d.)
Trial: 8395761
Drug: Captopril, 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 6.25 mg orally
Trial: 8395761
Drug: Enalapril, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 2.5 mg orally
Trial: 8395761
Drug: Perindopril, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril, 2 mg orally
Trial: 8395761
Drug: Enalaprilat, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat, 1.5 mg intravenously
Trial: 8395761
Drug: Perindoprilat, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat, 1.0 mg intravenously
Trial: 23914733
Drug: Combined VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined VR and upper limb conventional (ULC) therapy
Trial: 23914733
Drug: ULC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ULC therapy alone
Trial: 16952209
Drug: Gentamicin-collagen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-collagen treatment
Trial: 14610236
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF, filgrastim) 300 microg
Trial: 14610236
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg (oral) before G-CSF injection
Trial: 11391341
Drug: Recombinant granulocyte
RxNorm normalized name: Glycosylated recombinant granulocyte colony stimulating factor
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant granulocyte colony-stimulating factor (rG‐CSF) in subgroups '<2000 g' or 'neutropenia'
Trial: 2426590
Drug: Intravenous gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma globulin plus aspirin
Trial: 26926419
Drug: Multimodal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal drug injection
Trial: 26926419
Drug: No multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No multimodal drug injection (control group)
Trial: 20649979
Drug: Highly diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly diluted homeopathic drug (potency C12 = 1024), Dose: 5 globules taken 5 times per day over a maximum period of 5 days
Trial: 7826080
Drug: KW-2307 (KW)
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 (KW) 25 mg/m2
Trial: 7826080
Drug: Vindesine (VDS)
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (VDS) 3 mg/m2
Trial: 7826080
Drug: KW-2307 (KW)
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 (KW) with cisplatin (CDDP) 80 mg/m2
Trial: 7826080
Drug: Vindesine (VDS)
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (VDS) with cisplatin (CDDP) 80 mg/m2
Trial: 1784628
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg miglitol
Trial: 7821886
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acarbose
Trial: 28118174
Drug: Fesoterodine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine therapy (4-8 mg daily, n = 322)
Trial: 26023772
Drug: Clear water
RxNorm normalized name: Sunmark Bandage Clear Watershield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear water with soap during a daily shower
Trial: 17076980
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl 3.8 g/day plus ezetimibe 10 mg/day
Trial: 9540024
Drug: Miglitol (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (50, 100, 150, 200 mg t.i.d.)
Trial: 7972294
Drug: Caffeine treatment
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine treatment (overall)
Trial: 1096904
Drug: Indometacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (100 g/day)
Trial: 22228279
Drug: Provocative discography
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provocative discography plus intradiscal injection of dexamethasone (5 mg)
Trial: 22228279
Drug: Intridiscal injection
RxNorm normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intridiscal injection of saline (placebo)
Trial: 17622942
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (Copaxone) immunotherapy
Trial: 15683662
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation (EBI) 6 MV photons, total dose 24 Gy in six fractions in 2 weeks
Trial: 16011059
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no radiation therapy)
Trial: 12095383
Drug: Nevirapine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (200 mg oral dose to women after onset of labor and 2 mg/kg oral dose to newborns between 48 and 72 hours after birth)
Trial: 27755050
Drug: Standard organization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard organization of treatment (n = 21)
Trial: 19779025
Drug: Olanzapine orally
RxNorm normalized name: Olanzapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine orally disintegrating tablets (ODT) 10 mg o.d. for 8 days
Trial: 19779025
Drug: Olanzapine standard
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine standard oral tablets (OST) 10 mg o.d. for 8 days
Trial: 17687152
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg orally every morning for 7 days
Trial: 10673975
Drug: Remission-induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission-induction therapy followed by one consolidation course, with randomisation between autologous bone marrow transplantation (ABMT) and a second intensive consolidation course.
Trial: 10673975
Drug: Full protocol
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full protocol treatment completion.
Trial: 8608488
Drug: Granisetron (GRA)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (GRA) 3 mg i.v.
Trial: 8608488
Drug: Ondansetron (OND)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (OND) 24 mg i.v.
Trial: 8608488
Drug: Tropisetron (TRO)
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (TRO) 5 mg i.v.
Trial: 2012289
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.75 ml.kg‐1 with morphine 0.05 mg.kg‐1
Trial: 2012289
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.75 ml.kg‐1
Trial: 6128270
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Trial: 6128270
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Trial: 27044282
Drug: Planned invasive
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Planned invasive treatment
Trial: 27044282
Drug: Planned conservative
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Planned conservative treatment
Trial: 23376318
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections (4 quadrant injections of 0.5 mL triamcinolone, 40 mg/mL, n = 29)
Trial: 20675729
Drug: Amniotic membrane
RxNorm normalized name: Amniotic Membrane Human Ophthalmic Sheet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotic membrane transplantation in addition to conventional medical therapy
Trial: 19473600
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg administered in a fed state (after a high-fat, high-calorie breakfast)
Trial: 19473600
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg administered in a fasted state
Trial: 18039018
Drug: Topical terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical terbinafine (various formulations)
Trial: 9888867
Drug: 7 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/d omega-3 fatty acids for 4 weeks
Trial: 9888867
Drug: 7 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/d omega-6 or omega-9 fatty acids for 4 weeks
Trial: 7718754
Drug: Enalaprilat, 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat, 0.06 mg/kg
Trial: 1851142
Drug: Recombinant alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha‐2a interferon (Roferon‐A) at a dose of 5 MU/m2 S.C. three times a week and cisplatinum at dose levels of 15, 20, 25, 33, and 42 mg/m2/week given intravenously
Trial: 29537978
Drug: Transdermal rivastigmine
RxNorm normalized name: rivastigmine Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rivastigmine (9.5 mg/10 cm daily)
Trial: 29537978
Drug: Oral rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral rivastigmine (6 mg twice daily)
Trial: 26507721
Drug: Dulaglutide 1.5
RxNorm normalized name: dulaglutide 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 1.5 mg dose
Trial: 21077306
Drug: BPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPB with 0.2% ropivacaine at an infusion rate of 6 ml x hr(‐1) (n = 12)
Trial: 21077306
Drug: BPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPB with 0.2% ropivacaine at an infusion rate of 4 ml x hr(‐1) (n = 12)
Trial: 21077306
Drug: BPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPB with 0.2% ropivacaine at an infusion rate of 8 ml x hr(‐1) (n = 5)
Trial: 15906030
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of chemotherapy prior to surgery and three cycles after surgery (Group 1)
Trial: 15906030
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of chemotherapy prior to surgery (Group 2)
Trial: 15906030
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (six cycles)
Trial: 10505539
Drug: Hirudin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (0.4 mg/kg bolus, then 0.15 mg/kg per hour infusion)
Trial: 10505539
Drug: Heparin (5,000-U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5,000-U bolus, then 15-U/kg per hour infusion)